1Q08 sales were $301M (DKK 1,440M), +10% YoY in local currencies and +2% YoY in DKK. However, sales declined by 5% in DKK relative to 4Q07.
In short, NovoSeven has reached blockbuster status but continued growth is problematic due to the colossal cost per dose. (Lowering production cost is, of course, the impetus for GTC’s rFVIIa program with LFB.)
NVO has scrapped NovoSeven in favor of NN1731 (a short-acting FVIIa analogue) in the CABG indication after a phase-2 trial failed to show a benefit vs placebo.
Market Data 
Markets 
AI
